Placebo-controlled studies in rheumatoid arthritis: Ethical issues

Lancet

Volumn 353, Issue 9150, 1999, Pages 400-403

  Stein, C Michael ^a   Pincus, Theodore ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; PLACEBO;

ARTICLE; CLINICAL TRIAL; HUMAN; MEDICAL ETHICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0033616476     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)01373-7     Document Type: Note

References (37)

1. Ingelfinger F.J. The randomised clinical trial. N Engl J Med. 287:1972;100-101.
2. Pincus T., Stein C.M. What is the best source of useful data on the treatment of rheumatoid arthritis: clinical trials, clinical observations, or clinical protocols? J Rheumatol. 22:1995;1611-1617.
3. Feinstein A.R. An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med. 99:1983;544-550.
4. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-26.
5. Rennie D., Yank V. Disclosure to the reader of institutional review board approval and informed consent. JAMA. 277:1997;922-923.
6. Echt D.S., Liebson P.R., Mitchell LBet al. Mortality and morbidity in patients receiving encainide, flexainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 324:1991;781-788.
7. Clark P.I., Leaverton P.E. Scientific and ethical issues in the use of placebo controls in clinical trials. Annu Rev Public Health. 15:1994;19-38.
8. Rothman K.J., Michels K.B. The continuing unethical use of placebo controls. N Engl J Med. 331:1994;394-398.
9. Haslock I. The ethics of placebo treatment in rheumatoid arthritis drug trials [letter]. Br J Rheumatol. 28:1989;458.
10. Kirwan J.R., Currey H.L. Rheumatoid arthritis: disease-modifying antirheumatic drugs. Clin Rheum Dis. 9:1983;581-599.
11. Iannuzzi L., Dawson N., Zein N., Kushner I. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl Med. 309:1983;1023-1028.
12. Callahan L.F., Pincus T. Mortality in the rheumatic diseases. Arthritis Care Res. 8:1995;229-241.
13. Pincus T., Callahan L.F. The 'side effects' of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol. 32(suppl 1):1993;28-37.
14. Wolfe F., Cathey M.A. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol. 18:1991;1298-1306.
15. Reilly P.A., Cosh J.A., Maddison P.J., Rasker J.J., Silman A. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis. 49:1990;363-369.
16. Emery P. The Roche Rheumatology Prize Lecture: the optimal management of early rheumatoid disease: the key to preventing disability. Br J Rheumatol. 33:1994;765-768.
17. Pincus T., Callahan L.E. How many types of patients meet classification criteria for rheumatoid arthritis? Rheumatol. 21:1994;1385-1389.
18. Felson D.T., Anderson J.J., Meenan R.F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum. 33:1990;1449-1461.
19. Van Riel P.L., van der Heijde D.M., Nuver-Zwart I.H., van de Putte L.B. Radiographic progression in rheumatoid arthritis: results of 3 comparative trials. J Rheumatol. 22:1995;1797-1799.
20. Forre O. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: results of a 48-week multicenter study comparing low-dose cyclosporine with placebo: Norwegian Arthritis Study Group. Arthritis Rheum. 37:1994;1506-1512.
21. Boers M., Verhoeven A.C., Markusse HMet al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 350:1997;309-318.
22. Fries J.F., Williams C.A., Morfeld D., Singh G., Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum. 39:1996;616-622.
23. Egsmose C., Lund B., Borg Get al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double-blind placebo-controlled study. J Rheumatol. 22:1995;2208-2213.
24. O'Dell J.R., Haire C.E., Palmer W., et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 40:1997;842-848.
25. O'Dell J.R., Haire C.E., Palmer Wet al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 40:1997;842-848.
26. Kremer J.M. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after a mean of 13·3 years. Arthritis Rheum. 40:1997;984-985.
27. Hannonen P., Mottonen T., Hakola M., Oka M. Sulfasalazine in early rheumatoid arthritis: a 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum. 36:1993;1501-1509.
28. Borg G., Allander E., Berg E., Brodin U., From A., Trang L. Auranofin treatment in early rheumatoid arthritis may postpone early retirement: results from a 2-year double blind trial. J Rheumatol. 18:1991;1015-1020.
29. Tugwell P., Pincus T., Yocum Det al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis: the Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 333:1995;137-141.
30. Weinblatt M.E., Polisson R., Blotner SDet al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum. 36:1993;613-619.
31. Pasero G., Priolo F., Marubini Eet al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum. 39:1996;1006-1015.
32. Ward M.M., Leigh J.P., Fries J.F. Progression of functional disability in patients with rheumatoid arthritis: associations with rheumatology subspecialty care. Arch Intern Med. 153:1993;2229-2237.
33. Fries J.F., Williams C.A., Ramey D., Bloch D.A. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum. 36:1993;297-306.
34. Verheggen F.W., van Wijmen F.C. Myth and reality of informed consent in clinical trials. Med Law. 16:1997;53-69.
35. Lynoe N., Sandlund M., Dahlqvist G., Jacobsson L. Informed consent: study of quality of information given to participants in a clinical trial. BMJ. 303:1991;610-613.
36. Pincus T., Callahan L.F., Fuchs H.A., Larsen A., Kaye J. Quantitative analysis of hand radiographs in rheumatoid arthritis: time course of radiographic changes, relation to joint examination measures, and comparison of different scoring methods. J Rheumatol. 22:1995;1983-1989.
37. Fuchs H.A., Pincus T. Radiographic damage in rheumatoid arthritis: description by nonlinear models. J Rheumatol. 19:1992;1655-1658.